Reduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia

Journal of Magnetic Resonance Imaging

Volumn 33, Issue 6, 2011, Pages 1510-1516

  Cheung, Jerry S ^a,b   Au, Wing Yan ^a   Ha, Shau Yin ^a   Kim, Daniel ^c   Jensen, Jens H ^c   Zhou, Iris Y ^a   Cheung, Matthew M ^a   Wu, Yin ^a   Guo, Hua ^a,d   Khong, Pek Lan ^a   Brown, Truman R ^e   Brittenham, Gary M ^f   Wu, Ed X ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TSINGHUA UNIVERSITY   (China)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

cardiac MR; chelation therapy; ferritin; heart; hemosiderin; iron overload; MRI; RR2; thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOSOL; FEMALE; FERRITIN BLOOD LEVEL; HEART MUSCLE; HUMAN; IRON CHELATION; IRON OVERLOAD; MALE; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; REDUCED TRANSVERSE RELAXATION RATE; SENSITIVITY ANALYSIS; SUSPENSION; THALASSEMIA;

ADULT; BLOOD TRANSFUSION; CHELATING AGENTS; CHELATION THERAPY; CYTOSOL; FEMALE; FERRITINS; HEMOSIDERIN; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; THALASSEMIA; TIME FACTORS;

EID: 79958254314     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22553     Document Type: Article

References (41)

1. Mentzer WC, Kan YW,. Prospects for research in hematologic disorders: sickle cell disease and thalassemia. JAMA 2001; 285: 640-642. (Pubitemid 32656338)
2. Tuzmen S, Schechter AN,. Genetic diseases of hemoglobin: diagnostic methods for elucidating beta-thalassemia mutations. Blood Rev 2001; 15: 19-29. (Pubitemid 32506069)
3. Jensen PD,. Evaluation of iron overload. Br J Haematol 2004; 124: 697-711.
4. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-1193. (Pubitemid 39390442)
5. Olivieri NF, Brittenham GM,. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-761. (Pubitemid 27121266)
6. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-573. (Pubitemid 24265698)
7. Brittenham GM, Badman DG,. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101: 15-19. (Pubitemid 36025881)
8. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-2179. (Pubitemid 33139463)
9. Wood JC,. History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation 2009; 120: 1937-1939.
10. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120: 1961-1968.
11. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127: 348-355. (Pubitemid 39468951)
12. Harrison PM, Arosio P,. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996; 1275: 161-203. (Pubitemid 26248989)
13. Wixom RL, Prutkin L, Munro HN,. Hemosiderin: nature, formation, and significance. Int Rev Exp Pathol 1980; 22: 193-225. (Pubitemid 12152688)
14. Gossuin Y, Roch A, Muller RN, Gillis P,. Relaxation induced by ferritin and ferritin-like magnetic particles: the role of proton exchange. Magn Reson Med 2000; 43: 237-243. (Pubitemid 30075446)
15. Gossuin Y, Roch A, Muller RN, Gillis P, Lo Bue F,. Anomalous nuclear magnetic relaxation of aqueous solutions of ferritin: an unprecedented first-order mechanism. Magn Reson Med 2002; 48: 959-964. (Pubitemid 35402105)
16. Allen PD, St Pierre TG, Chua-anusorn W, Strom V, Rao KV,. Low-frequency low-field magnetic susceptibility of ferritin and hemosiderin. Biochim Biophys Acta 2000; 1500: 186-196. (Pubitemid 30060391)
17. Ghugre NR, Coates TD, Nelson MD, Wood JC,. Mechanisms of tissue-iron relaxivity: nuclear magnetic resonance studies of human liver biopsy specimens. Magn Reson Med 2005; 54: 1185-1193. (Pubitemid 41567198)
18. De Domenico I, Vaughn MB, Li L, et al. Ferroportin-mediated mobilization of ferritin iron precedes ferritin degradation by the proteasome. EMBO J 2006; 25: 5396-5404. (Pubitemid 44764148)
19. De Domenico I, Ward DM, Kaplan J,. Specific iron chelators determine the route of ferritin degradation. Blood 2009; 114: 4546-4551.
20. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI,. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 2004; 104: 1504-1510. (Pubitemid 39166531)
21. Jensen JH, Chandra R,. Theory of nonexponential NMR signal decay in liver with iron overload or superparamagnetic iron oxide particles. Magn Reson Med 2002; 47: 1131-1138. (Pubitemid 34587404)
22. Jensen JH, Tang H, Tosti CL, et al. Separate MRI quantification of dispersed (ferritin-like) and aggregated (hemosiderin-like) storage iron. Magn Reson Med 2010; 63: 1201-1209.
23. Sheth S, Tang H, Jensen JH, et al. Methods for noninvasive measurement of tissue iron in Cooley's anemia. Ann N Y Acad Sci 2005; 1054: 358-372. (Pubitemid 43031043)
24. Wu EX, Kim D, Tosti CL, et al. Magnetic resonance assessment of iron overload by separate measurement of tissue ferritin and hemosiderin iron. Ann N Y Acad Sci 2010; 1202: 115-122.
25. Cheung JS, Chow AM, Jensen JH, et al. MRI characterization of iron in soluble (ferritin-like) and particulate (hemosiderin-like) mixtures. Proc Int Soc Magn Reson Med 2007; 15: 1153.
26. Bulte JW, Miller GF, Vymazal J, Brooks RA, Frank JA,. Hepatic hemosiderosis in non-human primates: quantification of liver iron using different field strengths. Magn Reson Med 1997; 37: 530-536. (Pubitemid 27146831)
27. Guo H, Au WY, Cheung JS, et al. Myocardial T2 quantitation in patients with iron overload at 3 Tesla. J Magn Reson Imaging 2009; 30: 394-400.
28. Kim D, Jensen JH, Wu EX, Sheth SS, Brittenham GM,. Breathhold multiecho fast spin-echo pulse sequence for accurate R2 measurement in the heart and liver. Magn Reson Med 2009; 62: 300-306.
29. He T, Gatehouse PD, Anderson LJ, et al. Development of a novel optimized breathhold technique for myocardial T2 measurement in thalassemia. J Magn Reson Imaging 2006; 24: 580-585. (Pubitemid 44320560)
30. Cheung JS, Au WY, Ha SY, et al. Monitoring iron chelation effect in hearts of thalassaemia patients with improved sensitivity using reduced transverse relaxation rate (RR2). Proc Int Soc Magn Reson Med 2010; 18: 3660.
31. Pell GS, Briellmann RS, Waites AB, Abbott DF, Lewis DP, Jackson GD,. Optimized clinical T2 relaxometry with a standard CPMG sequence. J Magn Reson Imaging 2006; 23: 248-252. (Pubitemid 43191082)
32. Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003; 18: 33-39. (Pubitemid 36791266)
33. Atalay MK, Poncelet BP, Kantor HL, Brady TJ, Weisskoff RM,. Cardiac susceptibility artifacts arising from the heart-lung interface. Magn Reson Med 2001; 45: 341-345. (Pubitemid 32119018)
34. Storey P, Thompson AA, Carqueville CL, Wood JC, de Freitas RA, Rigsby CK,. R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging 2007; 25: 540-547. (Pubitemid 46355416)
35. Song R, Cohen AR, Song HK,. Improved transverse relaxation rate measurement techniques for the assessment of hepatic and myocardial iron content. J Magn Reson Imaging 2007; 26: 208-214. (Pubitemid 47235253)
36. Breuer W, Shvartsman M, Cabantchik ZI,. Intracellular labile iron. Int J Biochem Cell Biol 2008; 40: 350-354. (Pubitemid 351241220)
37. Selden C, Owen M, Hopkins JM, Peters TJ,. Studies on the concentration and intracellular localization of iron proteins in liver biopsy specimens from patients with iron overload with special reference to their role in lysosomal disruption. Br J Haematol 1980; 44: 593-603. (Pubitemid 10129170)
38. Shi H, Bencze KZ, Stemmler TL, Philpott CC,. A cytosolic iron chaperone that delivers iron to ferritin. Science 2008; 320: 1207-1210. (Pubitemid 351929507)
39. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL,. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003; 101: 4632-4639. (Pubitemid 36857840)
40. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855-861. (Pubitemid 40070775)
41. Song R, Lin W, Chen Q, Asakura T, Wehrli FW, Song HK,. Relationships between MR transverse relaxation parameters R*(2), R(2) and R′(2) and hepatic iron content in thalassemic mice at 1.5 T and 3 T. NMR Biomed 2008; 21: 574-580.